116 related articles for article (PubMed ID: 38480051)
1. Prognostic factors in clinicopathology of oesophagogastric adenocarcinoma: a single-centre longitudinal study of 347 cases over a 20-year period.
Huang Q; Lew E; Cheng Y; Huang K; Deshpande V; Shinagare S; Yuan X; Gold JS; Wiener D; Weber HC
Pathology; 2024 Jun; 56(4):484-492. PubMed ID: 38480051
[TBL] [Abstract][Full Text] [Related]
2. Lymphangiogenesis and prognostic significance of vascular endothelial growth factor C in gastro-oesophageal junction adenocarcinoma.
Xie LX; Zhai TT; Yang LP; Yang E; Zhang XH; Chen JY; Zhang H
Int J Exp Pathol; 2013 Feb; 94(1):39-46. PubMed ID: 23317352
[TBL] [Abstract][Full Text] [Related]
3. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery.
Vošmik M; Laco J; Sirák I; Dvořák J; Lochman P; Hodek M; Malá P; Rejchrt S; Repák R; Leško M; Ferko A; Ryška A; Melichar B; Petera J
Pathol Oncol Res; 2018 Apr; 24(2):373-383. PubMed ID: 28550507
[TBL] [Abstract][Full Text] [Related]
4. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
[TBL] [Abstract][Full Text] [Related]
5. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
Rivera F; Izquierdo-Manuel M; García-Alfonso P; Martínez de Castro E; Gallego J; Limón ML; Alsina M; López L; Galán M; Falcó E; Manzano JL; González E; Muñoz-Unceta N; López C; Aranda E; Fernández E; Jorge M; Jiménez-Fonseca P
Eur J Cancer; 2021 Mar; 145():158-167. PubMed ID: 33485079
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of clinicopathological features and prognosis between adenocarcinoma of esophagogastric junction and adenocarcinoma of gastric antrum].
Zhu Z; Wang Y; Li F; Gao J; Han B; Wang R; Xue Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):149-155. PubMed ID: 30799537
[TBL] [Abstract][Full Text] [Related]
7. Comparison of gastro-oesophageal junction carcinomas in Chinese versus American patients.
Huang Q; Fan X; Agoston AT; Feng A; Yu H; Lauwers G; Zhang L; Odze RD
Histopathology; 2011 Aug; 59(2):188-97. PubMed ID: 21884197
[TBL] [Abstract][Full Text] [Related]
8. The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
Curtis NJ; Noble F; Bailey IS; Kelly JJ; Byrne JP; Underwood TJ
J Surg Oncol; 2014 Mar; 109(3):202-7. PubMed ID: 24243140
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.
Propper D; Jones K; Anthoney DA; Mansoor W; Ford D; Eatock M; Agarwal R; Inatani M; Saito T; Abe M; Evans TR
BMC Cancer; 2016 Oct; 16(1):779. PubMed ID: 27724887
[TBL] [Abstract][Full Text] [Related]
10. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
[TBL] [Abstract][Full Text] [Related]
11. Esophageal adenocarcinoma heterogeneity in clinicopathology and prognosis: A single center longitudinal study of 146 cases over a 20-year period.
Huang Q; Lew E; Cheng Y; Shinagare S; Deshpande V; Gold JS; Wiener D; Weber HC
Ann Diagn Pathol; 2024 Jun; 70():152285. PubMed ID: 38518703
[TBL] [Abstract][Full Text] [Related]
12. How to classify adenocarcinomas of the esophagogastric junction: as esophageal or gastric cancer?
Gertler R; Stein HJ; Loos M; Langer R; Friess H; Feith M
Am J Surg Pathol; 2011 Oct; 35(10):1512-22. PubMed ID: 21934477
[TBL] [Abstract][Full Text] [Related]
13. Telomerase activity and patient survival after surgery for gastric and oesophageal cancer.
Usselmann B; Newbold M; Morris AG; Nwokolo CU
Eur J Gastroenterol Hepatol; 2001 Aug; 13(8):903-8. PubMed ID: 11507353
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.
Kundel Y; Sternschuss M; Moore A; Perl G; Brenner B; Goldvaser H
Cancer Med; 2020 Oct; 9(20):7613-7625. PubMed ID: 32869544
[TBL] [Abstract][Full Text] [Related]
15. Personalizing risk stratification by addition of PAK1 expression to TNM staging: improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma.
Li Z; Zou X; Xie L; Chen H; Chen Y; Yeung SC; Zhang H
Int J Cancer; 2015 Apr; 136(7):1636-45. PubMed ID: 25159681
[TBL] [Abstract][Full Text] [Related]
16. Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010.
Fontana E; Smyth EC; Cunningham D; Rao S; Watkins D; Allum WH; Thompson J; Waddell T; Peckitt C; Chau I; Starling N
Gastric Cancer; 2016 Oct; 19(4):1114-1124. PubMed ID: 26541768
[TBL] [Abstract][Full Text] [Related]
17. Identification of the distinct genomic features in gastroesophageal junction adenocarcinoma and its Siewert subtypes.
Geng Q; Lao J; Zuo X; Chen S; Bei JX; Xu D
J Pathol; 2020 Nov; 252(3):263-273. PubMed ID: 32715475
[TBL] [Abstract][Full Text] [Related]
18. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
Chau I; Norman AR; Cunningham D; Oates J; Hawkins R; Iveson T; Nicolson M; Harper P; Seymour M; Hickish T
Ann Oncol; 2009 May; 20(5):885-91. PubMed ID: 19164454
[TBL] [Abstract][Full Text] [Related]
19. Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma.
Spoerl S; Novotny A; Al-Batran SE; Lordick F; Thuss-Patience P; Pauligk C; Haller B; Feith M; Lorenzen S
Eur J Cancer; 2018 Feb; 90():26-33. PubMed ID: 29272782
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of
Knief J; Reddemann K; Lazar-Karsten P; Herhahn T; Petrova E; Wellner U; Thorns C
J Clin Pathol; 2017 Mar; 70(3):274-276. PubMed ID: 28011578
[No Abstract] [Full Text] [Related]
[Next] [New Search]
